While questions regarding efficacy are still awaiting results from ongoing and future randomized trials, these preclinical and clinical results already demonstrate promise for the use of CDK4/6 inhibitors in this subtype of breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.